Moneycontrol PRO
Sansaar

business

See 10% overall growth for Sun-Ranbaxy entity: Surajit Pal

or the investors who are holding the stock should continue to hold it but fresh entry should be made only if it corrects from the current levels, says Surajit Pal, pharma analyst at Prabhudas Lilladher.

first published: Mar 25, 2015 02:21 pm

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347